Rabbit Recombinant Monoclonal CYP3A5 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Human samples.
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
IP | WB | IHC-P | |
---|---|---|---|
Human | Tested | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Select an associated product type
A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:2732228, PubMed:10681376, PubMed:11093772, PubMed:12865317). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:2732228, PubMed:10681376, PubMed:11093772). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228).
Cytochrome P450 3A5, CYPIIIA5, Cytochrome P450-PCN3, CYP3A5
Rabbit Recombinant Monoclonal CYP3A5 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Human samples.
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
Yes
EPR4396
Affinity purification Protein A
Blue Ice
+4°C
Do Not Freeze
ab246337 is the carrier-free version of Anti-CYP3A5 antibody [EPR4396] ab108624.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This supplementary information is collated from multiple sources and compiled automatically.
CYP3A5 also known as cytochrome P450 3A5 is an enzyme involved in drug metabolism. It is part of the cytochrome P450 superfamily. The enzyme has a molecular weight of approximately 57 kDa. Scientists have identified CYP3A5 as an important player in the oxidative metabolism of various xenobiotics and endogenous compounds. It is predominantly expressed in the liver but is also found in the kidney and intestines. Variability in CYP3A5 expression across individuals can significantly impact drug clearance rates and pharmacokinetics.
CYP3A5 plays a significant role in the metabolism of many drugs and steroid hormones. This ability stems from its function as a monooxygenase in the metabolism of both exogenous and endogenous substrates. CYP3A5 is not necessarily part of a larger enzyme complex but it often acts in concert with other CYP3A enzymes within the liver. Variability in gene expression can result in different metabolizing capacities among individuals which scientists often relate to genetic polymorphisms that affect the CYP3A5*3 allele.
CYP3A5 is integral to the steroid hormone biosynthesis and drug metabolism pathways. It interacts closely with CYP3A4 frequently working together to metabolize substrates such as cortisol and testosterone. The pathway involving drug metabolism highlights the importance of these enzymes in the detoxification and clearance of pharmaceuticals which may influence drug efficacy and safety in patients. Through its involvement in steroid hormone biosynthesis CYP3A5 coordinates with other enzymes to regulate the levels of active hormones contributing to hormonal balance.
Scientists have linked variations in CYP3A5 expression and activity to hypertension and cancer. The role of CYP3A5 in hypertension is of particular interest due to its involvement in the metabolism of cortisol a hormone influencing blood pressure. Additionally altered CYP3A5 activity can affect the activation and clearance of chemotherapeutic agents impacting treatment outcomes in cancer. Researchers have noted that CYP3A5 shares functional relationships with proteins such as P-glycoprotein which plays roles in drug transport and resistance further connecting it to treatment efficacy and safety in these diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Anti-CYP3A5 antibody [EPR4396] ab108624 (unpurified) at 1/20 immunoprecipitating CYP3A5 in human fetal liver tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
All lanes: Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (Anti-CYP3A5 antibody [EPR4396] ab108624)
Predicted band size: 57 kDa
Observed band size: 52 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human colon tissue labelling CYP3A5 with unpurified Anti-CYP3A5 antibody [EPR4396] ab108624. Positive staining is shown.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling CYP3A5 with unpurified Anti-CYP3A5 antibody [EPR4396] ab108624 at 1/80. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human kidney tissue labelling CYP3A5 with unpurified Anti-CYP3A5 antibody [EPR4396] ab108624. Positive staining is shown.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Anti-CYP3A5 antibody [EPR4396] ab108624 (purified) at 1/50 immunoprecipitating CYP3A5 in human fetal liver tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
All lanes: Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (Anti-CYP3A5 antibody [EPR4396] ab108624)
Predicted band size: 57 kDa
Observed band size: 52 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human breast tissue labelling CYP3A5 with unpurified Anti-CYP3A5 antibody [EPR4396] ab108624. Negative staining is shown.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skeletal muscle tissue labelling CYP3A5 with unpurified Anti-CYP3A5 antibody [EPR4396] ab108624. Negative staining is shown.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human tonsil tissue labelling CYP3A5 with unpurified Anti-CYP3A5 antibody [EPR4396] ab108624. Negative staining is shown.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling CYP3A5 with purified Anti-CYP3A5 antibody [EPR4396] ab108624 at 1/250. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CYP3A5 antibody [EPR4396] ab108624).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com